Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Silodosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 20/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 20/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 20/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Silodosin SCHEMBL31017646 | 1.00 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| Silodosin SCHEMBL29967021 | 1.00 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| Silodosin SCHEMBL136973 | 1.00 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| Silodosin SCHEMBL10327491 | 1.00 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL8543706 | 0.98 | ADRA1D (0.96) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL8539364 | 0.98 | ADRA1D (0.96) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL16422042 | 0.94 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL16422051 | 0.94 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL16422170 | 0.94 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL16422017 | 0.94 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116063220-A | Preparation method of silodosin | 山西库邦生物医药科技有限公司 | 2023-05-05 | — | — | CN | claimed |
| WO-2012147107-A2 | NOVEL & IMPROVED PROCESSES FOR THE PREPARATION OF INDOLINE DERIVATIVES AND ITS PHARMACEUTICAL COMPOSITION | MSN LABORATORIES LIMITED (IN) | 2012-11-01 | — | — | WO | claimed |
| EP-1293198-B1 | Device for transdermal administration for the treatment of urinary tract disorders | SANOL ARZNEI SCHWARZ GMBH (DE) | 2005-02-09 | — | — | EP | claimed |
| EP-3750538-B1 | NON-HORMONAL METHODS FOR MALE CONTRACEPTION COMPRISING (R)-SILODOSIN | PHARMAJOR INT (LU) | 2024-08-14 | — | — | EP | disclosed |
| US-20240180871-A1 | MODIFIED-RELEASE SILODOSIN COMPOSITIONS AND USE THEREOF IN METHODS FOR MALE CONTRACEPTION | PHARMAJOR INCORPORATED (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2024112955-A1 | MODIFIED-RELEASE SILODOSIN COMPOSITIONS AND USE THEREOF IN METHODS FOR MALE CONTRACEPTION | PHARMAJOR INCORPORATED (US) | 2024-05-30 | — | — | WO | disclosed |
| CN-116063220-A | Preparation method of silodosin | 山西库邦生物医药科技有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115896060-A | Omega-transaminase mutant and application thereof | 合肥工业大学 | 2023-04-04 | — | — | CN | disclosed |
| CN-111763168-B | Preparation method of silodosin | 滁州市庆云医药有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-111217735-B | Preparation method of silodosin intermediate | 上海汇伦医药股份有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-11583518-B2 | Non-hormonal compositions and methods for male contraception | PHARMAJOR INTERNATIONAL (LU) | 2023-02-21 | — | — | US | disclosed |
| EP-1293198-A1 | Device for transdermal administration for the treatment of urinary tract disorders | SCHWARZ PHARMA AG (DE) | 2003-03-19 | — | — | EP | disclosed |
| US-6410554-B1 | ADRENERGIC ANTAGONIST | MERCK & CO., INC. | 2002-06-25 | — | — | US | disclosed |
| US-6310086-B1 | PREVENTION OR TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2001-10-30 | — | — | US | disclosed |
| EP-1057813-A1 | INDOLE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999048530-A1 | COMBINATION THERAPY FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999015202-A1 | REMEDIES FOR DYSURIA RESULTING FROM PROSTATIC HYPERTROPHY | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1999-04-01 | — | — | WO | disclosed |
| EP-0600675-B1 | Indoline compounds for the treatment of dysuria | KISSEI PHARMACEUTICAL (JP) | 1998-07-08 | — | — | EP | disclosed |
| US-5387603-A | Treating dysuria (painful urination) with less hypotension; FDA Orange book listed patent for silodosin | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1995-02-07 | — | — | US | disclosed |
| EP-0600675-A1 | Indoline compounds for the treatment of dysuria | Kissei Pharmaceutical Co., Ltd. (JP) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180871-A1 | MODIFIED-RELEASE SILODOSIN COMPOSITIONS AND USE THEREOF IN METHODS FOR MALE CONTRACEPTION | SHBG, MLN, SEPTIN8 | ADRA1A 1474/4885ADRA1D 853/4885ADRA1B 1037/4885 |
| US-11583518-B2 | Non-hormonal compositions and methods for male contraception | SHBG, NR5A1, ADRA1D | ADRA1A 4/4885ADRA1D 3/4885ADRA1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.